Streetwise Expert Interviews

R. Lee Buckler

Japan Gives a Hug to the Cell Therapy Industry: R. Lee Buckler

Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report, former regenerative medicine consultant R. Lee Buckler, now a vice president with RepliCel Life Sciences Inc., puts his consultant's hat back on to talk about Japan's hospitable stance on proposed cell therapies. He provides an update on the meaning of the new law and discusses a small cohort of companies poised to reap the advantages.

(10/22/14) More >
Read More Streetwise Interviews

How to Bargain Hunt for Hot Biotechs: Edison's Pooya Hemami

Every business day, research analyst Pooya Hemami scours the global markets for life science companies with upside flowing through their product pipelines. (10/15/14) More >

Newsletter Briefs

"ATHX is putting boots on the ground in Japan to develop a strategy there." (10/22/14) Athersys Inc. - The Life Sciences Report Interview with R. Lee Buckler More >

"MSB is potentially in the pole position in Japan." (10/22/14) Mesoblast Ltd. - The Life Sciences Report Interview with R. Lee Buckler More >

"RXII's molecules are designed specifically to facilitate the uptake of their therapeutic payload." (10/8/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >

"The patent for CPMA builds RNN's intellectual property fortress." (10/7/14) Rexahn Pharmaceuticals Inc. - Sharon di Stefano, Seeking Alpha More >

"The share buyback shows MSLP's new nature, one of avoiding dilution." (10/6/14) MusclePharm Corp. - Paulo Santos, Seeking Alpha More >

"INO's Ebola vaccine was effective in 100% of two test animal sets." (10/2/14) Inovio Pharmaceuticals Inc. - Matthew Smith, Seeking Alpha More >

"We like IPD, which has an early detection device for lymphedema." (10/2/14) ImpediMed Ltd. - The Life Sciences Report Interview with Scott Power More >

"We are very positive on TLT's technology. It's very promising." (9/25/14) Theralase Technologies Inc. - The Life Sciences Report Interview with Anita Dushyanth More >

Expert Analysis

"INO will target product development within infectious disease." (10/21/14) Inovio Pharmaceuticals Inc. - Ram Selvaraju, Aegis Capital More >

"With 5% U.S. market share, CUR's NSI-566 is a potential $500M drug." (10/15/14) Neuralstem Inc. - Jason Napodano, Seeking Alpha More >

"Expanding into advanced wound care is a main growth driver for MDXG." (10/13/14) MiMedx Group Inc. - Bruce Jackson, Lake Street Capital Markets More >

"We think THLD could become profitable in 2016 based on revenue from sales of TH-302." (10/13/14) Threshold Pharmaceuticals Inc. - George Zavoico, MLV & Co More >

"CUR's forward progress of the NSI-556 trial for SCI is welcome news." (10/13/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"CTH plans to complete three studies over Q4/14 and Q1/15." (10/9/14) Cynapsus Therapeutics Inc. - Ajay Tandon, SeeThruEquity More >

"Photos of RXII's treated patients showed significant improvement." (10/8/14) RXi Pharmaceuticals Corp. - Edward White, Laidlaw & Company More >

"We are increasing our price target for CTH." (10/2/14) Cynapsus Therapeutics Inc. - Nathan Cali, Noble Financial More >